Compare Mesoblast Limited (MESO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SYSCO Corporation — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while SYSCO Corporation trades at $85.09 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 18.2× Mesoblast Limited's market cap, and SYSCO Corporation pays a 2.61% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SYY | |
|---|---|---|
Market Cap | $2.21B | $40.32B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $91.16 |
52-Week Low | $12.88 | $69.30 |
Enterprise Value | $2.21B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
SYY trades at $85.24, up 1.63% with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings of $1.53 EPS, beating estimates, with revenue growth to $81.37B in 2025. Analyst consensus is bullish with 60% buy ratings and an $88.25 price target. Recent news highlights CEO discussions on CNBC and positive earnings coverage.
Outlook remains positive with steady revenue growth and efficiency initiatives driving margins. Risks include competitive pressures and macroeconomic uncertainty. The stock offers value with a P/S of 0.48 and dividend yield support, but high P/B of 15.12 warrants caution on valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
